Testing a repurposed add-on drug with Keytruda and Lenvima
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 3 study tests whether adding a repurposed drug to Keytruda and Lenvima (Len+Pem) helps people with advanced or recurrent endometrial cancer live longer and feel safer. It is designed for tumors that do not have certain immune-system markers (not MSI-H or dMMR).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older with confirmed endometrial (uterine lining) cancer that is endometrioid type, and your tumor is not MSI-H or dMMR
- Your cancer is advanced (Stage III/IV) or has come back after treatment
- Your cancer has grown or returned after platinum chemotherapy, and you can’t safely have curative surgery or radiation
- Your doctors can measure the cancer on scans (measurable or evaluable disease)
- You are able to start Keytruda plus Lenvima (Len+Pem) at the study doses
- Your general health is good enough (ECOG 0 or 1), you can last at least 12 weeks, and your blood pressure and kidney function meet limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether a repurposed drug can be safely added to Keytruda and Lenvima for women with advanced or recurrent endometrial cancer. It’s meant to help people who can’t have curative surgery or radiation after prior chemotherapy.
This Phase 2 trial tests whether envafolimab alone or combined with lenvatinib can slow or shrink advanced endometrial (uterine) cancer. It’s for people whose cancer has grown again or spread and who didn’t do well with standard platinum chemotherapy.
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for endometrial cancer that has come back after initial treatment with chemotherapy and immunotherapy. The study focuses on a specific type of cancer based on genetic testing and may help patients whose cancer didn't respond to standard first-line treatment.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This study tests a combination of two drugs (lenvatinib and pembrolizumab) plus focused radiation to the pelvis for a specific type of endometrial cancer that has returned or cannot be surgically removed. The goal is to see if this treatment is safe and effective for tumors that are pMMR and limited to the pelvic area.
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Hear when a new Advanced Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.